CD274 and neoplasm: Blockade of PD-1/PD-L1 axis by anti-PD-1 antibodies (pembrolizumab and nivolumab) or anti-PD-L1 antibodies (atezolizumab, avelumab, and durvalumab) allow T cells to maintain their anti-tumor activity in the tumor micro-environment.